Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Current Assets (2016 - 2025)

Alaunos Therapeutics (TCRT) has disclosed Current Assets for 15 consecutive years, with $2.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Assets fell 24.37% year-over-year to $2.7 million, compared with a TTM value of $2.7 million through Sep 2025, down 24.37%, and an annual FY2024 reading of $2.8 million, down 66.65% over the prior year.
  • Current Assets was $2.7 million for Q3 2025 at Alaunos Therapeutics, down from $3.7 million in the prior quarter.
  • Across five years, Current Assets topped out at $112.7 million in Q1 2021 and bottomed at $1.1 million in Q1 2025.
  • Average Current Assets over 5 years is $37.9 million, with a median of $18.8 million recorded in 2023.
  • The sharpest move saw Current Assets tumbled 84.64% in 2023, then fell 20.09% in 2025.
  • Year by year, Current Assets stood at $78.8 million in 2021, then tumbled by 31.75% to $53.8 million in 2022, then crashed by 84.64% to $8.3 million in 2023, then crashed by 66.65% to $2.8 million in 2024, then decreased by 2.54% to $2.7 million in 2025.
  • Business Quant data shows Current Assets for TCRT at $2.7 million in Q3 2025, $3.7 million in Q2 2025, and $1.1 million in Q1 2025.